Results of a randomized, double-blind, active-controlled clinical trial with propiverine extended release 30 mg in patients with overactive bladder-Reference-Cited by-同舟云学术

Results of a randomized, double-blind, active-controlled clinical trial with propiverine extended release 30 mg in patients with overactive bladder

Published:2016-05-13 Issue:1 Volume:119 Page:148-157
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

Leng Jing¹,Liao Limin²,Wan Ben³,Du Chuanjun⁴,Li Wei⁵,Xie Keji⁶,Shen Zhoujun⁷,Xu Zhuoqun⁸,Wu Shiliang⁹,Fang Zujun¹⁰,Ma Lulin¹¹,Han Shaomei¹²,Feustel Cornelia¹³,Yang Yong¹⁴,Madersbacher Helmut¹⁵

Affiliation:

1. Renji Hospital Affiliated to Shanghai JiaoTong University School of Medicine; Shanghai China

2. Beijing Boai Hospital; Beijing China

3. Beijing Hospital of the Ministry of Health; Beijing China

4. Second Affiliated Hospital Zhejiang University College of Medicine; Zhejiang China

5. Second Hospital of Hebei Medical University; Shijiazhuang China

6. Guangzhou First Municipal People's Hospital; Guangzhou China

7. Ruijin Hospital Affiliated to Shanghai JiaoTong University School of Medicine; Shanghai China

8. Wuxi People's Hospital; Wuxi China

9. Peking University First Hospital; Beijing China

10. Huashan Hospital Affiliated to Fudan University; Shanghai China

11. Peking University Third Hospital; Beijing China

12. Basic Medicine Institute of China Academy of Chinese Medical Sciences; Beijing China

13. Consultant for APOGEPHA Arzneimittel GmbH; Dresden Germany

14. Beijing Chaoyang Hospital affiliating Capital University of Medical Sciences; Beijing China

15. Medical University Innsbruck; Innsbruck Austria

Funder

Lee's Pharmaceutical Ltd, Hong Kong

APOGEPHA Arzneimittel GmbH, Dresden, Germany

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bju.13500/fullpdf

Reference39 articles.

1. Prevalence and burden of overactive bladder in the United States;Stewart;World J Urol,2003

2. Prevalence of the overactive bladder syndrome by applying the International Continence Society definition;Temml;Eur Urol,2005

3. Prevalence of overactive bladder, its under-diagnosis, and risk factors in a male urologic veterans population;Cheung;Int J Med Sci,2010

4. Prevalence and risk factors of overactive bladder syndrome in Fuzhou Chinese women;Zhang;Neurourol Urodyn,2006

5. Analysis of the risk factors for overactive bladder on the basis of a survey in the community;Jo;Korean J Urol,2012

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incontinencia urinaria;Actualización en Medicina de Familia;2023-09-01

2. Current and Emerging Pharmacological Targets and Treatments of Urinary Incontinence and Related Disorders;Pharmacological Reviews;2023-03-14

3. Efficacy and safety of propiverine in patients with overactive bladder and neurogenic detrusor overactivity;Pharmacy & Pharmacology International Journal;2022-04-18

4. Antimuscarinic Pharmacotherapy for Overactive Bladder;Contemporary Pharmacotherapy of Overactive Bladder;2018-09-26